Canocapavir

CAS No. 2137847-19-7

Canocapavir( —— )

Catalog No. M35755 CAS No. 2137847-19-7

Canocapavir (ZM-H1505R) is a novel orally available HBV coat protein modulator with antiviral activity that induces conformational changes in the linker region of the HBV core protein, and can be used for the treatment of hepatitis B virus.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 454 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Canocapavir
  • Note
    Research use only, not for human use.
  • Brief Description
    Canocapavir (ZM-H1505R) is a novel orally available HBV coat protein modulator with antiviral activity that induces conformational changes in the linker region of the HBV core protein, and can be used for the treatment of hepatitis B virus.
  • Description
    Canocapavir (ZM-H1505R) has orally antiviral activity. Canocapavir is a HBV capsid inhibitor that can be used in the research of Chronic hepatitis B. .
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HBV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2137847-19-7
  • Formula Weight
    562.39
  • Molecular Formula
    C27H21BrFN5O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 300 mg/mL (533.44 mM; Ultrasonic (<60°C)
  • SMILES
    C(CC=1C=C2C(=CC1)NC(=O)N2)N3[C@@H](C=4C(=NN(C4)C5=CC=C(Br)C=C5)C6=CC=C(F)C=C6)OCC3=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf?sfvrsn=8544ca1e_3&download=true
molnova catalog
related products
  • GLP-26

    GLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM.

  • DVR-01

    DVR-01 is an HBV capsid inhibitor and can be used in studies about the treatment of Hepatitis B virus (HBV) infection and related conditions.

  • JNJ-632

    JNJ-632 (JNJ632) is a novel potent HVV capsid assembly modulator and HBV replication inhibitor.